Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gains from Investment Securities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Gains from Investment Securities for 14 consecutive years, with -$16000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Gains from Investment Securities rose 92.59% to -$16000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was -$16000.0, a 97.24% increase, with the full-year FY2024 number at -$114000.0, up 58.09% from a year prior.
  • Gains from Investment Securities was -$16000.0 for Q2 2024 at NovaBay Pharmaceuticals, up from -$194000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.8 million in Q2 2020 to a low of -$5.2 million in Q4 2020.
  • A 5-year average of -$886916.7 and a median of -$205000.0 in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 377100.0% in 2020; the steepest drop was 21808.33% in 2020.
  • NovaBay Pharmaceuticals' Gains from Investment Securities stood at -$5.2 million in 2020, then rose by 11.42% to -$4.6 million in 2021, then skyrocketed by 78.85% to -$976000.0 in 2022, then surged by 82.58% to -$170000.0 in 2023, then surged by 90.59% to -$16000.0 in 2024.
  • Per Business Quant, the three most recent readings for NBY's Gains from Investment Securities are -$16000.0 (Q2 2024), -$194000.0 (Q1 2024), and -$170000.0 (Q4 2023).